Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

As part of the segment, Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru and Dr. Aronne discussed ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and ...

Caremark negotiated an undisclosed lower net price for Wegovy over Zepbound on its standard formularies, offering savings on Novo Nordisk's drug to clients that opt into those plans. But ...

Q1 Wegovy sales rose 85% to DKK 17.36 billion; Ozempic up 18% to DKK 32.72 billion. Novo Nordisk's Q1 sales hit $10.89 billion, missing the $11.64 billion consensus estimate. Don’t miss this ...

Shares of Novo Nordisk jumped nearly 7% on Wednesday after it said sales of its blockbuster Wegovy weight loss drug were seen improving in the second half of the year as the availability of ...

Novo Nordisk said first-quarter sales of Wegovy were 17.36 billion Danish crowns ($2.64 billion), declining 13% from the previous quarter, and below the 18.7 billion crowns expected by analysts.